LPA (lysophosphatidic acid, 1-acyl-2-hydroxy-sn-glycero-3-phosphate), is a growth factor-like lipid mediator that regulates many cellular functions, many of which are unique to malignantly transformed cells. The simple chemical structure of LPA and its profound effects in cancer cells has attracted the attention of the cancer therapeutics field and drives the development of therapeutics based on the LPA scaffold. In biological fluids, LPA is generated by ATX (autotaxin), a lysophospholipase D that cleaves the choline/serine headgroup from lysophosphatidylcholine and lysophosphatidylserine to generate LPA. In the present article, we review some of the key findings that make the ATX–LPA signalling axis an emerging target for cancer therapy.
Controlling cancer through the autotaxin–lysophosphatidic acid receptor axis
Mari Gotoh, Yuko Fujiwara, Junming Yue, Jianxiong Liu, SueChin Lee, James Fells, Ayako Uchiyama, Kimiko Murakami-Murofushi, Stephen Kennel, Jonathan Wall, Renukadevi Patil, Renuka Gupte, Louisa Balazs, Duane D. Miller, Gabor J. Tigyi; Controlling cancer through the autotaxin–lysophosphatidic acid receptor axis. Biochem Soc Trans 1 February 2012; 40 (1): 31–36. doi: https://doi.org/10.1042/BST20110608
Download citation file: